Literature DB >> 11561092

SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates.

B Bontempi1, K T Whelan, V B Risbrough, T S Rao, J J Buccafusco, G K Lloyd, F Menzaghi.   

Abstract

Preclinical and clinical data have suggested the potential use of nicotinic acetylcholine receptor (nAChR) ligands for treating cognitive dysfunction associated with neurodegenerative diseases, such as Alzheimer's disease. SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a novel nAChR ligand with predominant agonist subtype selectivity for beta4 subunit-containing human neuronal nAChRs, was tested in a variety of cognitive paradigms in aged rodents and nonhuman primates after acute and repeated administration. Subcutaneous administration of SIB-1553A improved delayed nonmatching to place performance in aged mice. In aged rhesus monkeys, intramuscular and oral administration of SIB-1553A improved choice accuracy in a delayed matching to sample task. SIB-1553A improved performances in these spatial and nonspatial working memory tasks but was less effective at improving performances in spatial reference memory tasks (i.e., aged rodents exposed to a discrimination task in a T-maze or trained to locate a hidden platform in a water maze). These data suggest that SIB-1553A has a predominant effect on attention/working memory processes. SIB-1553A also induced the release of acetylcholine in the hippocampus of aged rats and was equally effective whether administered acutely or repeatedly (6 weeks of daily subcutaneous administration). Thus, rats repeatedly treated with SIB-1553A exhibit neither tolerance nor sensitization to the effects of the compound. The SIB-1553A-induced cognitive improvement may be in part related to an increase in cholinergic function. The present study provides additional support for the use of subtype-selective nAChR ligands as a potential therapy for the symptomatic treatment of specific cognitive deficits (such as attention/working memory deficits) associated with aging and neurological diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561092

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  Neurobiology of nAChRs and cognition: a mini review of Dr. Jerry J. Buccafusco's contributions over a 25 year career.

Authors:  Alvin V Terry; Michael W Decker
Journal:  Biochem Pharmacol       Date:  2011-06-12       Impact factor: 5.858

2.  Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties.

Authors:  Patrick Lippiello; Sharon R Letchworth; Gregory J Gatto; Vincent M Traina; Merouane Bencherif
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

3.  In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.

Authors:  Altaf S Darvesh; Richard T Carroll; Werner J Geldenhuys; Gary A Gudelsky; Jochen Klein; Charles K Meshul; Cornelis J Van der Schyf
Journal:  Expert Opin Drug Discov       Date:  2011-02       Impact factor: 6.098

Review 4.  Pharmacological enhancement of memory and executive functioning in laboratory animals.

Authors:  Stan B Floresco; James D Jentsch
Journal:  Neuropsychopharmacology       Date:  2010-09-15       Impact factor: 7.853

5.  A critical examination of best dose analysis for determining cognitive-enhancing potential of drugs: studies with rhesus monkeys and computer simulations.

Authors:  Paul L Soto; Jesse Dallery; Nancy A Ator; Brian R Katz
Journal:  Psychopharmacology (Berl)       Date:  2013-03-26       Impact factor: 4.530

6.  Effects of nicotine and mecamylamine on cognition in rhesus monkeys.

Authors:  Simon N Katner; Sophia A Davis; Amber J Kirsten; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

Review 7.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 8.  Septohippocampal acetylcholine: involved in but not necessary for learning and memory?

Authors:  Marise B Parent; Mark G Baxter
Journal:  Learn Mem       Date:  2004 Jan-Feb       Impact factor: 2.460

9.  Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm.

Authors:  Angela Y Gemperle; Kevin H McAllister; Hans-Rudolf Olpe
Journal:  Psychopharmacology (Berl)       Date:  2003-06-24       Impact factor: 4.530

10.  Cholinergic connectivity: it's implications for psychiatric disorders.

Authors:  Elizabeth Scarr; Andrew S Gibbons; Jaclyn Neo; Madhara Udawela; Brian Dean
Journal:  Front Cell Neurosci       Date:  2013-05-03       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.